U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Drug Shortages

FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Report a Drug Shortage | Contact Us | FAQ | Background Info | Get Email Alerts | Download Current Drug Shortages

Start Over | Back to Previous Screen

Lorazepam Injection
Status: Currently in Shortage
»Date first posted: 05/03/2018
»Therapeutic Categories: Neurology

Expand all

Akorn Pharmaceuticals (Reverified 05/19/2021)

Company Contact Information:
800-932-5676

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Lorazepam Injection 2 mg/mL (NDC 17478-040-01) Available Demand increase for the drug

Amphastar Pharmaceuticals, Inc./IMS (Reverified 08/12/2022)

Company Contact Information:
800-423-4136

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
LORAZEPAM INJECTION, USP, C IV [2 mg/ mL](NDC 76329-8261-1) Backorder due to the increase in demands Other

Hikma Pharmaceuticals USA, Inc. (formerly West-Ward) (Reverified 08/26/2022)

Company Contact Information:
800-631-2174

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Ativan (lorazepam) Injection 2 mg/mL, 1 mL vial (NDC 0641-6001-25) This presentation is temporarily on backorder. Demand increase for the drug
Ativan (lorazepam) Injection 2 mg/mL, 10 mL vial (NDC 0641-6000-10) This presentation is temporarily on backorder. Demand increase for the drug
Ativan (lorazepam) Injection 4 mg/mL, 1 mL vial (NDC 0641-6003-25) This presentation is temporarily on backorder. Demand increase for the drug
Ativan (lorazepam) Injection 4 mg/mL, 10 mL vial ((NDC 0641-6002-10) This presentation is temporarily on backorder. Demand increase for the drug
Lorazepam Injection, USP 2 mg/mL, 1 mL vial (NDC 0641-6044-25) This presentation is temporarily on backorder. Demand increase for the drug
Lorazepam Injection, USP 2 mg/mL, 10 mL vial (NDC 0641-6046-10) This presentation is temporarily on backorder. Demand increase for the drug
Lorazepam Injection, USP 4 mg/mL, 1 mL vial (NDC 0641-6045-25) This presentation is temporarily on backorder. Demand increase for the drug
Lorazepam Injection, USP 4 mg/mL, 10 mL vial (NDC 0641-6002-10) This presentation is temporarily on backorder. Demand increase for the drug

Hospira, Inc. (Revised 09/12/2022)

Company Contact Information:
844-646-4398

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
4 mg/mL; Carpuject Luer Lock Glass Syringe (NDC 00409-1539-31) Discontinued Discontinuation of the manufacture of the drug
2 mg/mL; Carpuject Luer Lock Glass Syringe (NDC 00409-1985-30) Limited Supply Available. Next Delivery: September 2022; Estimated Recovery: January 2023 Demand increase for the drug
2 mg/mL; 1 mL Multiple Dose Glass Fliptop Vial (NDC 00409-6778-02) Next Delivery: October 2022; Estimated Recovery: January 2023 Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay Other
4 mg/mL; 1 mL Multiple Dose Glass Fliptop Vial (NDC 00409-6779-02) Discontinued Discontinuation of the manufacture of the drug
20 mg/10 mL (2 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-6780-02) Discontinued Discontinuation of the manufacture of the drug
Back to Top